Try GOLD - Free
India Announces Major Tax Cuts To Boost Investment
Bio Spectrum
|November 2019
USV Private Limited, an Indian multinational pharmaceutical, and biotechnology company based in Mumbai reacting quickly to the developments and leveraging on the government’s surprise corporate tax rate cut on September 20 announced that it will proceed with its investment of Rs 400 crore on a new state-of-art formulation plant at Vadodara in Gujarat.
-
The company noted that the announcement by the government has provided the much-needed boost to the pharmaceutical manufacturing sector that requires investments to provide world-class medicines to the population, at large. While the tax cut announced by the government will increase capital spending and generate employment in the pharmaceutical sector, these investments will also go a long way to improve sustainability and capacities in pharmaceutical manufacturing.
In order to promote growth and investment in India, the Union Minister for Finance & Corporate Affairs Nirmala Sitaraman announced that the Government of India has brought in the Taxation Laws (Amendment) Ordinance 2019 to make certain amendments in the Income-tax Act 1961 and the Finance (No. 2) Act 2019.
The Finance Minister said “a new provision has been inserted in the Income-tax Act with effect from FY 2019-20 which allows any domestic company an option to pay income-tax at the rate of 22% subject to the condition that they will not avail any exemption/ incentive. The effective tax rate for these companies shall be 25.17% inclusive of surcharge & cess. Also, such companies shall not be required to pay Minimum Alternate Tax (MAT).”
She also noted that in order to attract fresh investment in manufacturing and thereby provide boost to ‘Make-in-India’ initiative of the government, another new provision has been inserted in the Income-tax Act with effect from FY 2019-20 which allows any new domestic company incorporated on or after October 1, 2019 making fresh investment in manufacturing, an option to pay income-tax at the rate of 15%. This benefit is available to companies that do not avail of any exemption/incentive and commences their production on or before March 31, 2023. The effective tax rate for these companies shall be 17.01% inclusive of surcharge & cess. Also, such companies shall not be required to pay MAT.
This story is from the November 2019 edition of Bio Spectrum.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Bio Spectrum
Bio Spectrum
India's Strategic Shift Towards High-Quality, Low-Cost MedTech
India's healthcare infrastructure continues to face significant strain from the rising prevalence of non-communicable diseases (NCDs), contributing around 66 per cent of the mortalities in the country, underscoring the need for scalable continuous monitoring, early diagnosis, and therapeutic devices. Yet, advanced imaging systems, analysers, surgical tools, or robotic devices remain very expensive due to import reliance, high logistics costs, and maintenance/ service contracts. Segments showing strongest traction today are diagnostics (point-of-care devices, rapid tests, compact imaging devices), remote monitoring/wearable devices, and therapeutic devices such as surgical robotic systems, renal care systems, and wound care devices.
4 mins
December 2025
Bio Spectrum
How India's Diabetes Crisis is Driving Med Devices Market
A growing diabetic population in India is a blessing for the care devices market. Both Indian and global diabetes care devices have taken this growing demand for various devices, kits as an opportunity to expand their market share. But the scope in rural areas seems a bit challenging for various companies due to less awareness about the disease, affordability etc. Let's look at this growing diabetes care devices market.
9 mins
December 2025
Bio Spectrum
Thermo Fisher Scientific invests Rs 160 Cr+ to expand Bengaluru R&D facility
Thermo Fisher Scientific's expanded Research and Development (R&D) Centre of Excellence was inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM).
1 min
December 2025
Bio Spectrum
Motorica strengthens India presence with appointment of Kavinder Beniwal as COO
Motorica, a Delhi-based medtech company specialising in assistive technologies and medical cybernetics, has announced the appointment of Kavinder Beniwal as Chief Operational Officer (COO) of Motorica India.
1 min
December 2025
Bio Spectrum
Cabinet approves major expansion of PG and UG medical education capacity
Union Cabinet chaired by the Prime Minister Narendra Modi has approved the Phase-Ill of the Centrally Sponsored Scheme (CSS) for strengthening and upgradation of existing State Government/ Central Government Medical Colleges/Standalone PG Institutes/ Government Hospitals for increasing 5,000 PG seats and extension of the CSS for upgradation of existing government medical colleges for increasing 5,023 MBBS seats with an enhanced cost ceiling of Rs 1.5 crore per seat.
1 min
December 2025
Bio Spectrum
Dr Sharvil Patel steps in as Indian Pharmaceutical Alliance President
The Indian Pharmaceutical Alliance (IPA) has announced a leadership transition, with Dr Sharvil Patel, Managing Director of Zydus Lifesciences and former Vice President of IPA, assuming the role of President.
1 min
December 2025
Bio Spectrum
PAG-led Sekhmet Pharmaventures announces appointment of Mukesh Agarwal as CFO
Hyderabad-based Sekhmet Pharmaventures, a fast-emerging global API/CDMO player led by leading Asia-focused investment firm PAG, has announced the appointment of Mukesh Agarwal as its new Chief Financial Officer (CFO).
1 min
December 2025
Bio Spectrum
Monash University Malaysia and Tata Chemicals forge healthcare researchfocused partnership
The importance of gastrointestinal health is a key focus for researchers and innovators, as highlighted by the partnership between Monash University Malaysia and Tata Chemicals Limited.
1 min
December 2025
Bio Spectrum
"India has the talent and ambition to lead globally in advanced therapies, biologics, and oncology"
Thermo Fisher Scientific has recently announced plans to make significant investments in India's biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. Central to this expansion strategy are two major facilities in Genome Valley, Hyderabad, i.e. Bioprocess Design Center (BDC), and Customer Experience Center (CEC). In addition, the company has invested more than Rs 160 crore this year to expand its R&D facility in Bengaluru. For further understanding on these new developments, BioSpectrum spoke in detail to Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific. Edited excerpts;
4 mins
December 2025
Bio Spectrum
"AI is a transformative enabler that's reshaping how science is conducted in labs"
2025 witnessed multiple new initiatives taken by Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, for the Indian market. These initiatives included establishment of an India Solutions Center in Manesar; and a Biopharma Experience Center in Hyderabad. 2025 also saw Nandakumar Kalathil stepping in as the new Country General Manager for Agilent India. With over 25 years of experience in the analytical industry, Nanda brings extensive expertise in leadership, team management, and customer relations. To find out more about the company's growth plans in 2026 in India, BioSpectrum interacted with Nandakumar Kalathil, Country General Manager for Agilent India in detail. Edited excerpts:
4 mins
December 2025
Translate
Change font size
